PRMT5 inhibitors
Grant
US12595248B2
Kind: B2
Apr 07, 2026
Assignee
Merck Sharp & Dohme LLC
Inventors
Michelle Machacek, Michael D. Altman, Chunghui Huang, Michael H. Reutershan, David L. Sloman, Phieng Siliphaivanh, Sebastian E. Schneider, Charles S. Yeung, David J. Witter, Craig R. Gibeau, Yingchun Ye
Abstract
The present invention provides a compound of Formula (I) and the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are PRMT5 inhibitors. Also provided are methods of making compounds of Formula I, pharmaceutical compositions comprising compounds of Formula I, and methods of using these compounds to treat cancer, sickle cell, and hereditary persistence of foetal hemoglobin (HPFH) mutations.
CPC Classifications
C07D 401/00
C07D 405/00
C07D 413/00
C07D 451/00
C07D 471/00
C07D 487/00
C07D 498/00
Filing Date
2020-12-14
Application No.
17783975
Claims
32